H. Hunter Handsfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
H. Hunter Handsfield has a total of 438 co-authors. Here are the top co-authors by number of shared publications:
- Jeanne Marisa Marrazzo
National Institute of Allergy and Infectious Diseases, Bethesda, USA
3 shared publications P. Frederick Sparling
2 shared publicationsA. Clinton White
1 shared publicationA. George Smulian
1 shared publicationAdrian V.S. Hill
1 shared publicationAlan Barrett
1 shared publication
Latest Publications
- 1 August 2013
- Published by Elsevier in Contraception
- Vol. 88 (2) , 299-300
Managing prevalent and problematic sexually transmitted infections
- 1 August 2013
- Published by Elsevier in Contraception
- Vol. 88 (2) , 299-300
Managing prevalent and problematic sexually transmitted infections
- 1 January 2010
- Published by Elsevier
CONTRIBUTORS
- Open Access
- 15 June 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (12) , 1664
Methicillin-Resistant Staphylococcus aureus Infections in Sex Partners: What Is a Sexually Transmitted Disease?
To The Editor —It was interesting to read the article by Cook et al. [1] regarding the possible heterosexual transmission of methicillin-resistant Staphylococcus aureus (MRSA). However, I question the conclusion. The article documents shared genital-area MRSA infections in 3 couples, clinically and by concordance of MRSA strains found between partners. However, exchange of traditional sexually transmitted pathogens requires direct genital, oral-genital, or anal-genital contact, whereas staphylococci and other cutaneous flora are readily exchanged by intimate, nonsexual exposure, such as by sharing beds and perhaps towels or other fomites. Furthermore, the affected anatomic areas do not necessarily imply a route of transmission. Warmth and moisture undoubtedly enhance the susceptibility of the genitals and perigenital areas to staphylococcal colonization and symptomatic infection.
- 15 June 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (12) , 1664
Open AccessMethicillin-Resistant Staphylococcus aureus Infections in Sex Partners: What Is a Sexually Transmitted Disease?
To The Editor —It was interesting to read the article by Cook et al. [1] regarding the possible heterosexual transmission of methicillin-resistant Staphylococcus aureus (MRSA). However, I question the conclusion. The article documents shared genital-area MRSA infections in 3 couples, clinically and by concordance of MRSA strains found between partners. However, exchange of traditional sexually transmitted pathogens requires direct genital, oral-genital, or anal-genital contact, whereas staphylococci and other cutaneous flora are readily exchanged by intimate, nonsexual exposure, such as by sharing beds and perhaps towels or other fomites. Furthermore, the affected anatomic areas do not necessarily imply a route of transmission. Warmth and moisture undoubtedly enhance the susceptibility of the genitals and perigenital areas to staphylococcal colonization and symptomatic infection.
- 1 June 2007
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 34 (6) , 339-343
Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life
Suppressive therapy has not been studied during the first year after acquisition of genital herpes, the time of maximum frequency of reactivation, potential for transmission, and impact on quality of life. The objective of this study was to evaluate the effectiveness of suppressive therapy with valacyclovir initiated within 3 months of infection. The authors conducted a double-blind, randomized, controlled trial of 1.0 g valacyclovir daily versus placebo for 6 months in 119 patients. Herpes simplex virus (HSV) type 2 and HSV-1 were documented in 75 and 22 patients, respectively. In intention-to-treat analysis, annualized rates of symptomatic recurrences for valacyclovir and placebo, respectively, were 1.7 +/- 2.7 (mean +/- standard deviation) and 3.4 +/- 4.0 outbreaks per year (P = 0.012). Time to first recurrence was 80 +/- 47 days for valacyclovir and 54 +/- 49 days for placebo (P = 0.001). The differences in favor of valacyclovir were greatest in patients with confirmed HSV-2 infection. The Recurrent Genital Herpes Quality of Life score in HSV-2 infected patients rose 11.9 +/- 11.1 points for valacyclovir and 5.9 +/- 9.1 points for placebo (P = 0.040). Early suppressive therapy with valacyclovir reduces symptomatic recurrent outbreaks, especially in patients with HSV-2 infection. Valacyclovir therapy was associated with improved herpes-related quality of life.
- 1 June 2007
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 34 (6) , 339-343
Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life
Suppressive therapy has not been studied during the first year after acquisition of genital herpes, the time of maximum frequency of reactivation, potential for transmission, and impact on quality of life. The objective of this study was to evaluate the effectiveness of suppressive therapy with valacyclovir initiated within 3 months of infection. The authors conducted a double-blind, randomized, controlled trial of 1.0 g valacyclovir daily versus placebo for 6 months in 119 patients. Herpes simplex virus (HSV) type 2 and HSV-1 were documented in 75 and 22 patients, respectively. In intention-to-treat analysis, annualized rates of symptomatic recurrences for valacyclovir and placebo, respectively, were 1.7 +/- 2.7 (mean +/- standard deviation) and 3.4 +/- 4.0 outbreaks per year (P = 0.012). Time to first recurrence was 80 +/- 47 days for valacyclovir and 54 +/- 49 days for placebo (P = 0.001). The differences in favor of valacyclovir were greatest in patients with confirmed HSV-2 infection. The Recurrent Genital Herpes Quality of Life score in HSV-2 infected patients rose 11.9 +/- 11.1 points for valacyclovir and 5.9 +/- 9.1 points for placebo (P = 0.040). Early suppressive therapy with valacyclovir reduces symptomatic recurrent outbreaks, especially in patients with HSV-2 infection. Valacyclovir therapy was associated with improved herpes-related quality of life.
- Open Access
- 15 January 2007
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 195 (2) , 303
Correlates of sexually transmitted infections in young women.
To The Editor —The well‐designed study by Boyer et al. of predictors of sexually transmitted infections in young women [1] is a useful contribution that should help guide prevention strategies. However, its value is compromised by the decision to display only the combined outcome for 3 infections. Despite the obvious similarities in anatomic sites of infection and mode of transmission, the epidemiological characteristics and determinants of chlamydial infection, gonorrhea, and trichomoniasis are quite different—dramatically so in some settings. With prevalences of 12.2%, 2.1%, and 1.7%, respectively, the reported correlates probably are valid for Chlamydia trachomatis infection but perhaps not for the others. At the same time, the determinants of chlamydial infection are diluted by the inclusion of gonorrhea and trichomoniasis. The authors should provide the multivariate associations for chlamydial infection (e.g., a modification of their table 2) and should summarize the correlates found for gonorrhea and trichomoniasis.
- 15 January 2007
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 195 (2) , 303
Open AccessCorrelates of sexually transmitted infections in young women.
To The Editor —The well‐designed study by Boyer et al. of predictors of sexually transmitted infections in young women [1] is a useful contribution that should help guide prevention strategies. However, its value is compromised by the decision to display only the combined outcome for 3 infections. Despite the obvious similarities in anatomic sites of infection and mode of transmission, the epidemiological characteristics and determinants of chlamydial infection, gonorrhea, and trichomoniasis are quite different—dramatically so in some settings. With prevalences of 12.2%, 2.1%, and 1.7%, respectively, the reported correlates probably are valid for Chlamydia trachomatis infection but perhaps not for the others. At the same time, the determinants of chlamydial infection are diluted by the inclusion of gonorrhea and trichomoniasis. The authors should provide the multivariate associations for chlamydial infection (e.g., a modification of their table 2) and should summarize the correlates found for gonorrhea and trichomoniasis.